Microcap Ledger Pulmatrix, Inc. $PULM
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Framingham, MA
- Fiscal year end
- December 31
- Shares outstanding
- 3,652,285 [10-Q 2026-08-13]
What the company doesAI summary of filing
Pulmatrix, Inc. is a biopharmaceutical company developing inhaled therapeutic products using its proprietary iSPERSE dry powder delivery platform. The company's clinical-stage product candidates target migraine and respiratory diseases, including PUR3100 for acute migraine, PUR1800 for acute exacerbations of chronic obstructive pulmonary disease, and PUR1900 for allergic bronchopulmonary aspergillosis. The company is currently seeking opportunities to monetize its iSPERSE technology and clinical assets in connection with a proposed merger with Cullgen Inc., and has paused development of its product candidates pending completion of that transaction. [10-K 2026-02-26]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$2.21M | −$2.17M | $2.17M | [S-4/A 2026-09-17] |
| FY ended Dec 2025 | — | −$5.16M | −$5.43M | $4.09M | [DEFM14A 2026-09-25] |
| FY ended Dec 2024 | $7.81M | −$9.56M | −$10.72M | $9.52M | [S-4/A 2026-09-17] |
- Quarterly cash burn
- −$1.09M
- Cash runway Estimate
- ~6 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2025-03-17 | 3,652,285 | [10-K 2025-03-21] |
| 2025-05-12 | 3,652,285 | [10-Q 2025-05-15] |
| 2025-07-31 | 3,652,285 | [10-Q 2025-08-06] |
| 2025-10-13 | 3,652,285 | [10-Q 2025-10-16] |
| 2026-02-23 | 3,652,285 | [10-K 2026-02-26] |
| 2026-05-11 | 3,652,285 | [10-Q 2026-05-15] |
| 2026-06-15 | 3,652,285 | [10-K/A 2026-06-16] |
| 2026-08-13 | 3,652,285 | [10-Q 2026-08-13] |
- Shelf registration
- S-3 filed 2026-06-04; no effectiveness notice found in EDGAR [S-3 2026-06-04]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-07 | 424B3 | Prospectus or prospectus supplement |
| 2026-10-05 | S-3/A | Registration statement |
| 2026-09-25 | 424B3 | Prospectus or prospectus supplement |
| 2026-08-13 | 10-Q | Quarterly report |
| 2026-08-13 | 8-K | Results of operations |
| 2026-08-07 | S-3/A | Registration statement |
| 2026-06-16 | 10-K/A | Amended report |
| 2026-06-04 | S-3 | Registration statement |
| 2026-05-15 | 10-Q | Quarterly report |
| 2026-05-15 | 8-K | Results of operations |
| 2026-04-22 | 13D | Beneficial ownership report (5%+ holder) |
| 2026-04-21 | 8-K | Regulation FD disclosure; Other events |
Alerts for $PULM
Email me when Pulmatrix, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.